Sign up United Kingdom
Proactive Investors - Run By Investors For Investors

Motif Bio says two new US patents push exclusivity period over antibiotic out to 2037

The American Patent and Trademark Office has issued what's called a notice of allowance for two patent claims
petrie dish
The company has a market-ready antibiotic

Motif Bio PLC (LON:MTFB, NASDAQ:MTFB) said the grant of two US patents pushes its exclusivity over antibiotic iclaprim out to 2037.

It follows what’s called a notice of allowance for patents governing the drug’s use to treat bacterial infections, including acute bacterial skin and skin structure infections, hospital-acquired bacterial pneumonia and Staphylococcus aureus lung infections in patients with cystic fibrosis. 

WATCH: Motif Bio secures new patents around optimal dose for iclaprim out to 2037

"These US patents provide additional exclusivity for iclaprim in the treatment of bacterial infections well into 2037,” said chief executive Graham Lumsden. 

“We are actively building our intellectual property portfolio in the U.S. and other key markets around the globe."

Having successfully negotiated two Phase III clinical trials, Motif is gearing up to take its next-generation antibiotic to market.

View full MTFB profile View Profile

Motif Bio Plc Timeline

Related Articles

scientist with vial
September 25 2018
The AIM-listed drug developer is at the vanguard of advances in the emerging field of immuno-oncology
August 21 2018
The company aims to revolutionise the HPA production process, eschewing the laborious bauxite-sourced method.
June 21 2018
Genedrive has signed sales agreement with Sysmex Corporation for the distribution of the HCV ID to EMEA and Asia Pacific and with Mumbai- based ARKRAY to distribute the kit in India

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use